₹24 crore hit the reported margin.But the worry is regarding slower growth of its brand-named export formulation products, which contribute to higher margins.
This was about 19% lower year-on-year. Analysts attribute the lower brand-named formulations sales to the continuing issues with logistics and the lockdown in many countries.
Nevertheless, the domestic formulations business clocked decent 21% growth during the quarter, which is encouraging.“Ipca’s domestic business may have seen higher sales of hydroxychloroquine in Q4, and we expect the benefit of this drug to be delivered in Q1FY21 as well.
The fourth quarter’s benefit was for just about 15-20 days. However, in the first quarter we expect these gains to be spread out over the.